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Abstract: Oxidative stress has been proposed as a major mechanism of damage to motor neurons
associated with the progression of amyotrophic lateral sclerosis (ALS). Astrocytes are the most
numerous glial cells in the central nervous system and, under physiological conditions, protect
neurons from oxidative damage. However, it is uncertain how their reactive phenotype may affect
motor neurons during ALS progression. In two different ALS mouse models (SOD1G93A and FUS-
R521C), we found that increased levels of proinflammatory interleukin 6 facilitate glutathione (GSH)
release from the liver to blood circulation, which can reach the astrocytes and be channeled towards
motor neurons as a mechanism of antioxidant protection. Nevertheless, although ALS progression is
associated with an increase in GSH efflux from astrocytes, generation of reactive oxygen species also
increases, suggesting that as the disease progresses, astrocyte-derived oxidative stress could be key
to motor-neuron damage.
Keywords: amyotrophic lateral sclerosis; liver; astrocytes; motor neurons; mitochondria; glutathione;
oxidative stress
1. Introduction
Amyotrophic lateral sclerosis (or ALS) is a disease of the central nervous system (CNS)
characterized by a progressive degeneration of motor neurons (MNs) in the cerebral cortex
(upper MNs), brainstem and spinal cord (lower MNs) [1]. The consequence is muscle
weakness, which can progress to paralysis, spreading from one body region to another [2].
Most cases (90–95%) have no genetic background (sporadic ALS, SALS), and their cause is
unknown, whereas in 5–10% of cases, a specific genetic mutation (the most common are
found in C9orf72, SOD1, FUS, or TARDBP) is the main underlying mechanism (familial
ALS, FALS) [3]. In the pathophysiology of the disease, neuroinflammation and oxidative
stress are main mechanisms leading to neurodegeneration and MN death [4].
Progression of the disease is associated with reactive glia- and immunity-dependent
neuroinflammation [5]. As a consequence, an increase in levels of inflammation-related
cytokines can be detected in the cerebrospinal fluid (CSF) and blood of murine models
and ALS patients [6]. Interleukin 6 (IL6) is among these cytokines [6,7]. IL6 seems to
have important function in the CNS, i.e., neurogenesis and response of neurons and glial
cells following different types of injuries [8]. However, although it is difficult to evaluate
inflammation of the CNS or the relationship between neuroinflammation and disease
progression in ALS patients, it has been reported that the common IL6 receptor 358 Ala
variant (IL6R358Ala) and trans-signaling are disease modifiers in ALS [7].
Glutathione (L-γ-glutamyl-L-cysteinyl-glycine; GSH), the most prevalent non-protein
thiol in mammalian cells and a physiological antioxidant, is involved in many cellular
functions [9]. Cys availability and γ-glutamyl-cysteine synthase activity are rate-limiting
Antioxidants 2021, 10, 2007. https://doi.org/10.3390/antiox10122007 https://www.mdpi.com/journal/antioxidants
Antioxidants 2021, 10, 2007 2 of 15
factors for the synthesis of GSH [10]. A decrease in antioxidant defense associated with
alterations in GSH metabolism have been suggested as potentially negative factors involved
in the progression of ALS [11]. Astrocytes are the most abundant type of macroglial cells
in the CNS [12] and provide Cys and GSH to neurons [13]. It seems obvious that this
function and the pro-inflammatory reactive response of astrocytes during ALS progression
are in contradiction.
We found that IL6 plays a role in inducing the release of liver GSH in models of
metastatic melanoma [14]. Hepatic GSH is considered the main systemic reservoir of this
tripeptide and may be released to the blood and reach other organs and cells [15]. We
explored whether this mechanism is also activated in ALS murine models, as well as its
impact on GSH levels and generation of reactive oxygen species (ROS) in astrocytes.
2. Materials and Methods
2.1. Mice
Control (wild-type, WT) B6SJLF1/J mice https://www.jax.org/strain/100012 (ac-
cessed on 1 December 2020) (The Jackson Laboratory, Mount Desert Island, ME, USA).
B6.Cg-Tg(SOD1*G93A)1Gur/J https://www.jax.org/strain/004435 (accessed on 1 De-
cember 2020) mice, which are hemizygous for the SOD1G93A transgene with transgenic
expression of a G93A mutant form of human SOD1. B6; SJL-Tg(Prnp-FUS*R521C)3313Ejh/J
https://www.jax.org/strain/026406 (accessed on 1 December 2020) mice, where the major-
ity of the transgenic FUS-R521C protein is nuclear.
2.2. Neurological Score
Neurological score in mice was determined weekly, by visual inspection, starting at
approx. postnatal day 45. Neurological score is based on the scale of Weydt et al. [16].
Scores indicate the following: “0” a healthy mouse; “1” the presence of tremors in the
hind legs; “2” difficulties in separating the hind legs when suspended by the tail; “3”
difficulties walking; “4” unable to walk on all four legs, so access to food and water has to
be facilitated. At a score of “5” (unable to right themselves), the animals are euthanized for
ethical reasons. Onset is defined as the earliest time when mice show symptoms (score < 4)
for ≥2 consecutive weeks.
2.3. Rotarod Test
This test is widely used to evaluate the neuromotor coordination of rodents. We used
a touchscreen rotarod of Panlab/Harvard Apparatus (Cornellá de Llobregat, Spain). Each
animal was given three trials, and the maximum period (seconds) that it could remain on a
rotating axle (3.5 cm diameter; speed of rotation 15 rpm) without falling was recorded. The
test was stopped after an arbitrary limit of 180 s. In the first 2 weeks, an adaptation period
of three trials was performed before beginning the test recordings.
2.4. Isolation and Incubation of Hepatocytes
We followed the Berry and Friend method [17]. Hepatocytes were purified from
the crude cell suspension by density gradient centrifugation in a vertical rotor [18]. The
crude suspension (50 mg dry wt in 2 mL) was added to a medium (40 mL) containing
40% (v/v) of Percoll, 3% (w/v) of defatted bovine serum albumin, 10% DMEM, 10 mM
MOPS, 120 mM NaCl, and 6.7 mM KCl, 1.2 mM CaCl2 and adjusted to pH 7.4 with 0.1 N
NaOH. Centrifugation was performed at 4 ◦C in a Beckman-Coulter Optima XL-100K
(7 × 104 gav for 15 min). Metabolic viability and integrity of isolated hepatocytes was
assayed as previously described [18]. For incubations in Erlenmeyer flasks, hepatocytes
(10–12 mg dry wt/mL) were suspended at 37 ◦C in KHBM (pH 7.4) containing 1.3 mM
CaCl2. The gas atmosphere was 95% O2–5% CO2.
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2.5. Glutathione and Glutathione Disulfide Levels
Glutathione (GSH) and glutathione disulfide (GSSG) were measured by liquid chromatography–
mass spectrometry (LC/MS) as previously described [19]. Cell processing followed the
published methodology, where rapid N-ethylmaleimide derivatization was used to prevent
GSH auto-oxidation [20].
2.6. Cerebrospinal, Blood and Liver Sample Collection
Whole-blood samples (0.5 mL) were obtained from the saphenous vein, collected in
standard red-topped Becton Dickinson (Franklin Lakes, NJ, USA) tubes and allowed to
clot for 30 min. Samples were centrifuged at 1500× g × 10 min (4 ◦C). Supernatants were
stored at −80 ◦C. Samples of CSF were obtained as described in detail by Lim et al. [21].
Liver samples were quickly dissected, washed at 4 ◦C in KHBM (pH 7.4) without Ca2+ or
Mg2+ and containing 0.5 mM EGTA, dried on tissue paper and frozen in liquid nitrogen.
2.7. Cytokine Levels
Simultaneous quantification of different cytokines in the blood serum or CSF was
obtained using xMAP technology and a MAGPIX Luminex 200 platform (Thermo Fisher
Scientific, Waltham, MA, USA), as recently described in detail [6]. The results were analyzed
with xPONENT 4.2® software (Luminex, Austin, TX, USA) and expressed as pg/mL.
2.8. Anti-IL6 and Anti-IL6R Monoclonal Antibodies
Rat anti-mouse-IL-6 IgG1 monoclonal antibody (mAb) (BioXCell, BE0046, Lebanon,
NH, USA, RRID AB1107709) or rat anti-mouse-IL-6R IgG2 mAb (BioXCell, BE0047, RRID
AB1107588) was administered at a dose of 400 µg (i.p.) per mouse daily, based on previously
reported in vivo effective doses [22,23].
2.9. Isolation, Culture and Perifusion of Astrocytes
Isolation and culture of astrocytes from mouse adult spinal cords was based on the
methodology described by Beaudet et al. [24]. A perifusion system was designed for
cultured astrocytes, where a modified cultured flask was designed to have an inflow tube
placed across the flask screw cap and an outflow tube placed on the flask wall opposite
the screw cap. The system included a reservoir for the culture medium (including a gas
diffuser to ensure its saturation using a mixture of O2/CO2 (19:1)), a roller pump, a bubble
trap and a filter (Amicon YM30, Bedford, MA, USA) placed at the screw cap. The culture
flask was partially submerged in a thermostatized water bath at a constant temperature of
37 ◦C. Effluent flow was monitored continuously for O2 and pH with Philips electrodes.
The perifusion flow rate was of 2 mL/min.
2.10. H2O2 and O2•− Generation Assays
Determination of H2O2 generation was based on H2O2-dependent oxidation of ho-
movanillic acid (4-hydroxy-3-methoxyphenylacetic acid) to a highly fluorescent dimer
(2,2′-dihydroxydiphenyl-5,5′-diacetic acid) mediated by horseradish peroxidase [25].
O2•− was quantitated using an electrochemical biosensor, as previously described [26].
To this end, a Co3(PO4)2 nanorod/glassy carbon electrode was applied in situ to electro-
chemically detect O2•− released from cells (5 × 105/mL) in real time. To ensure accuracy
of measured O2•− concentrations, cell culture medium inside the device was mildly stirred
during measurement of cell-released O2•−. A CHI760 electrochemical workstation (CH
Instruments Inc., Austin, TX, USA) was used for electrochemical measurements.
2.11. Analysis of Amino Acids
Arterial blood was collected from the left ventricle into a heparinized syringe/tube.
After centrifugation (10 min, 800× g), plasma was collected, and protein was precipitated
by mixing 1 mL of plasma and 4 mL of 3.75% (w/v) sulphosalicylic acid in 0.3 M-lithium
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citrate buffer (pH 2.8). The supernatant (0.5 mL) was injected into an LA8080 high-speed
amino-acid analyzer (Hitachi, Tokyo, Japan) for determination of amino acids.
2.12. RT-PCR
RNA was extracted using Qiagen RNAeasy mini kits (Hilden, Germany). Quantitative
and qualitative analyses of RNA samples were performed using a 2100 Bioanalyzer (Agi-
lent Technologies, Santa Clara, CA, USA). cDNA was obtained using a random hexamer
primer and a MultiScribe reverse transcriptase kit as recommended by the manufacturer
(Taq-Man RT Reagents; Thermo Fisher Scientific). PCR master mix and AmpliTaq Gold
DNA polymerase were added to the specific primers (Sigma Genosys, Haverhill, UK),
as previously reported [19], for GCL (γ-glutamylcysteine ligase, catalytic subunit), GGT
(γ-glutamyl transpeptidase), SOD (superoxide dismutases) 1 and 2, CAT (catalase), GPX2
(glutathione peroxidase 2), GSR (glutathione reductase) and G6PDH (glucose-6-P dehydro-
genase). For real-time quantification of mRNA relative to GAPDH, a SYBR Green I assay
and an iCycler detection system (Biorad, Hercules, CA, USA) were used. Relative gene
expression is expressed as fold change. The threshold cycle (CT) was determined, and the
relative gene expression was expressed as fold change = 2−∆(∆CT), where ∆CT = CT target
− CT GAPDH and ∆(∆CT) = ∆CT treated − ∆CT control.
2.13. Enzyme Activities
GCL activity was determined by measuring the rate of ADP formation at 37 ◦C in
a medium containing Tris/HCl buffer (pH 8.2), KCl, ATP, phosphoenolpyruvate, L-Glu,
L-α-aminobutyrate, MgCl2, EDTA, NADH, pyruvate kinase and lactate dehydrogenase.
GGT activity was measured using glycylglycine as a γ-glutamyl acceptor substrate and γ
-glutamyl-4-nitroanilide and its carboxy derivative, γ-glutamyl-3-carboxy-4-nitroanilide,
as donor substrates. SOD activity was measured using cyanide in the assay medium
to distinguish the mangano-type enzyme (SOD2) from the cuprozinc type (SOD1). To
measure CAT, activity samples were incubated in the presence of an H2O2 solution for
2 min prior to rapid mixing of the incubation enzymatic reaction mixture with a cobalt-
bicarbonate reagent, which assesses non-reacting H2O2. Catalase activity is always directly
proportional to the rate of dissociation of H2O2. GPX (selenium-dependent) activity was
measured using H2O2 as a substrate in Tris-HCl buffer with the addition of NaN3 and
EDTA (pH 8.5) at an incubation temperature of 37 ◦C. GSR activity follows the reduction
of GSSG to GSH by monitoring the oxidation of NADPH monitored by a decrease in
absorbance at 340 nm (see [25] and references therein).
2.14. Oxygen Consumption
O2 concentration and rate of O2 consumption in isolated astrocytes was continuously
recorded using a high-resolution oxygraph (OROBOROS INSTRUMENTS Corp., Innsbruck,
Austria). Isolated astrocytes were resuspended in respiration medium (DMEM 4500 mg/L
glucose to which was added 5 mM pyruvate) that had been pre-warmed to 37 ◦C. A
volume of 2.0 mL of cell suspension was added to the O2 electrode chamber, where it
was magnetically stirred and kept at 37 ◦C. The chamber was sealed, and the cells were
incubated until a stable respiratory rate was reached.
2.15. Western Blotting
Western blots were run, as previously described [25]. Proteins were transferred to
a nitrocellulose membrane and subjected to Western blotting with specific anti-human
monoclonal antibodies (OriGene, Rockville, MD, USA; and Abcam, Cambridge, UK).
Blots were developed using horseradish-peroxidase-conjugated secondary antibody and
enhanced chemiluminescence (ECL system; GE HealthCare Life Sciences, Piscataway, NJ,
USA). Protein bands were quantified using laser densitometry.
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2.16. Expression of Results and Statistical Analyses
Data are presented as the means ± SD for the indicated number of different experi-
ments. Statistical analyses were performed using Student’s t test, and p values of <0.05
were considered significant. Survival data were analyzed with Kaplan–Meier curves and
LogRank (Mantel-Cox) tests.
3. Results
3.1. Neuromotor Evaluation of ALS Mouse Models
Neuromotor functions were studied in SOD1G93A and FUS-R521C mice using a stan-
dardized neurological score (designed to assess hind-limb function) (Figure 1A) and the
rotarod performance test (a measure of balance, coordination, physical condition and
motor planning) (Figure 1B). As shown in Figure 1, the onset of the symptomatology is
around postnatal week 12 in SOD1G93A mice and postnatal week 7 in the FUS-R521C
model. An advanced state of disease progression was well established around postnatal
weeks 17–18 (SOD1G93A) and 17–19 (FUS-R521C). The survival rate for both models is dis-
played in Figure 1C. Based on these data, further experiments were performed comparing
measurements at the onset of the symptomatology and at an advanced state of progression.
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Figure 1. Functional performance and neuromotor coordination in SOD1G93A and FUS-R521C mice. Neurological score (A),
rotarod test (B) and survival (C) were assessed in SOD1G93AQ and FUS-R521C mice at different times in the progression of
the disease. Taking into account the % of animals that died before reaching the advanced progression status, to assess the
neurological score and the rotarod test, their number was increased so that n (20 animals) was the same both at onset and at
advanced progression. In wild-type controls (n = 20) the neurological score was equal to 0 and the time for the rotarod test
wa 1200 s in all cases. Both tests were performed twice a w ek. On the days of the week on which t e anim ls were not
subjected to tes s, they were trained i the rotarod for 20 min. Co trol experiments performed in wild-type mic (n = 10)
rendered a neurological score of 0 and performance time of 1200 s in the rotarod test in all cases. * p < 0. 1 comparing
values obtained in amyotrophic lateral sclerosis (ALS) mice versus wild-type controls.
3.2. GSH Synthesis and Release in Hepatocytes from ALS Mice
Under physiological conditions, the liver is the main reservoir and source of circulating
GSH [27]. We studied the rates of GSH synthesis and efflux in isolated hepatocytes from
wild-type (WT), SOD1G93A and FUS-R521C mice. As shown in Table 1, in the presence of
amino-acid precursors, GSH synthesis and efflux significantly increase in both models at
Antioxidants 2021, 10, 2007 6 of 15
an advanced state of disease progression, thus suggesting that an ALS-induced signaling
mechanism likely promotes those changes.
Table 1. Glutathione (GSH) synthesis and efflux in isolated hepatocytes from wild-type and ALS mice. The initial GSH
concentration was 5.2 ± 0.3 µmol/g in isolated hepatocytes from wild-type mice, 5.0 ± 0.4 and 4.0 ± 0.3 µmol/g in
isolated hepatocytes from SOD1G93A mice (at onset and advanced state of progression, respectively) and 4.8 ± 0.4 and
3.7 ± 0.3 µmol/g in isolated hepatocytes from FUS-R521C mice (at onset and advanced state of progression, respectively).
Hepatocytes were incubated in 10-mL Erlenmeyer flasks (final volume 2 mL) for 60 min (see Methods) in the presence or
absence of amino-acid precursors for GSH synthesis (5 mM Gln, 2 mM Gly, 1 mM Ser, 1 mM N-acetylcysteine) [28]. Only
L-amino acids were used. Glucose (5 mM) and bovine serum albumin (2%) were present in all incubations. Rates of GSH
synthesis were calculated from total GSH content in incubations at 0, 20, 40 and 60 min. Rates of glutathione efflux were
calculated from contents of GSH and glutathione disulfide (GSSG) in the extracellular medium at 0, 20, 40 and 60 min. All
values are means ± SD for 7–8 observations. For both groups, the significance test refers to the comparison of rates in





WT SOD1G93A FUS-R521C WT SOD1G93A FUS-R521C
Additions Onset Adv. Onset Adv. Onset Adv. Onset Adv.
None 2 ± 0.3 3 ± 0.4 * 5 ± 1 ** 2 ± 0.5 4 ± 1 ** 2 ± 0.5 4 ± 0.7 ** 5 ± 2 ** 3 ± 1 4 ± 1 *
L-Amino acids 22 ± 5 24 ± 4 31 ± 4 * 23 ± 3 30 ± 4 * 9 ± 3 11 ± 3 21 ± 4 ** 10 ± 2 20 ± 3 **
We also measured liver and blood GSH levels. As shown in Table 2 and as compared
to values obtained in the wild-type mice, liver GSH levels decrease in both ALS mouse
models at an advance state of progression, a fact that correlates with a decrease in the ratio
of synthesis/efflux (Table 1). However, the increase in liver GSH efflux does not cause the
consequent increase in circulating GSH; in fact, GSH decreases in the circulating blood in
both models (Table 2), a fact suggesting that blood GSH may be bypassed for metabolism.
This experimental evidence raises the question of how and where GSH flow is directed
during ALS progression.
Table 2. Blood and liver GSH in wild-type and ALS mice. Blood and liver samples were obtained and treated as described
in Methods. Data are means ± SD for 10–12 different mice. * p < 0.01 comparing values obtained in ALS mice versus
wild-type controls.
WT SOD1G93A FUS-R521C
Onset Adv. Onset Adv.
Blood GSH (µmol/gHb) 7.2 ± 0.5 7.0 ± 0.4 4.5 ± 0.4 * 7.3 ± 0.6 5.0 ± 0.5 *
Liver GSH (µmol/g of tissue) 6.9 ± 0.6 6.0 ± 0.5 3.5 ± 0.4 * 6.4 ± 0.5 3.9 ± 0.3 *
3.3. IL6 Induces GSH Efflux in Hepatocytes
It is well known that ALS is associated with neuroinflammation and an increase in
proinflammatory cytokines in plasma and CSF (see e.g., Obrador [6]). We measured some
of these cytokines in both biological fluids in our experimental models at an advanced
state of disease progression. As shown in Figure 2, as compared to healthy wild-type mice,
proinflammatory cytokine levels increase. As introduced above, IL6 signaling, in particular,
could play a role in increasing the release of liver GSH. We tested this hypothesis in the ALS
models (at an advanced state of progression) by administering anti-IL6 mAbs or anti-IL6R
mAbs in vivo. As compared to controls treated with physiological saline, both types of
antibodies decreased the rate of GSH efflux from hepatocytes (Table 3), thus proving, in
two different models, that IL6 is a main cytokine responsible for the increase in hepatic
GSH efflux during ALS progression. In parallel experiments, we found that treatment
with anti-IL6 mAbs is also associated with an increase in GSH levels in the liver (Table 3).
Blood GSH levels also increased (Table 3). Therefore, either the metabolic use of circulating
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GSH decreases or GSH is released to the blood by other organs/tissues as a consequence
of anti-IL6 treatment. In order to answer this paradox, we looked at GSH levels, GCL
activity and Cys/cystine uptake in the kidneys and lungs (two organs with a significant
content of GSH). As shown in Table 4, anti-IL6R treatment induces a significant decrease in
GSH in both organs (suggesting that more GSH is released to the blood) and an increase
in GCL activity and Cys/cystine uptake (which implies a higher level of GSH synthesis).
These results suggest a systemic adaptation to the treatment (involving kidneys and lungs,
although it could involve more organs). This is an adaptation that would explain the
increase observed in blood GSH (Table 3).
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[35S]cystine (PerkinElmer, Waltham, MA, USA). Data are mean values ± SD for n = 5–6. * p < 0.05, ** p < 0.01 comparing
data for each parameter obtained in anti-IL6R-treated mice versus controls treated with physiological saline.
SOD1G93A FUS-R521C
Kidneys Lungs Kidneys Lungs
Anti-IL6R − + − + − + − +
GSH
(µmol/g of tissue) 3.2 ± 0.4 1.4 ± 0.4 ** 1.7 ± 0.3 0.9 ± 0.3 ** 3.0 ± 0.5 1.2 ± 0.4 ** 1.5 ± 0.3 0.8 ± 0.2 **
GCL
(U/g of tissue) 92 ± 17 155 ± 26 ** 49 ± 15 96 ± 24 * 85 ± 21 148 ± 36 * 41 ± 8 88 ± 12 **
Cys uptake (nmol/mg prot·min) 1.2 ± 0.3 2.5 ± 0.8 * 0.7 ± 0.1 1.6 ± 0.4 ** 1.0 ± 0.2 2.0 ± 0.4 ** 0.6 ± 0.1 1.2 ± 0.3 **
Cystine uptake (nmol/mg prot·min) 11.5 ± 1.5 16.9 ± 2.7 * 5.4 ± 1.0 10.3 ± 1.7 ** 13.1 ± 1.7 19.5 ± 2.6 ** 5.9 ± 0.9 9.4 ± 1.8 **
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In order to answer whether this treatment leads to a rescue in the progression of
the disease, we looked at neuromotor function, survival and the number of viable motor
neurons that could be isolated from anti-IL6R-treated mice. As shown in Figure 3, it is
evident that anti-IL6R treatment significantly improves all these parameters. Nevertheless,
behind this anti-IL6-dependent rescue, a decrease in the IL6-dependent proinflammatory
effects is also possible.
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Figure 3. Effect of in vivo treatment with anti-IL6 mAbs on neuromotor function, survival, and MN viability of ALS mouse
models. Antibody administration (one dose per day from week 17 to week 19), rotarod test (as in Figure 1), and isolation of
MN were performed, as de cribed in Methods. Data re mean values ± SD for n = 20. * p < 0. 5 comparing we ks 18–21
versus week 17, + p < 0.05 comparing data obtained in anti-IL6R-treated mice versus controls treated with physiol gical
saline.
3.4. GSH Synthesis in Astrocytes Is Highly Dependent on Extracellular GSH Sup ly
Based on the fact that astrocytes provide GSH to neurons [13], we investigated whether
GSH levels in astrocytes are affected during ALS progression. For this purpose, we use a
perifusion system (see Methods) to perfuse the cultured astrocytes with a constant flow
of medium containing the same GSH levels measured in the blood of ALS mice (Table 5).
Supply of amino-acid precursors is not limited during ALS progression (Table 6A). As
shown in Table 5, GSH levels in astrocytes decrease at an advanced state of progression
(approx. to 50%, as compared to the levels found in astrocytes isolated from WT mice
or from ALS mice at the onset of symptomatology). Nevertheless, the decrease in GSH,
paradoxically, is associated with an increase in GCL activity, the rate-limiting step in GSH
synthesis (Table 5). GSSG levels also increase significantly, thus suggesting an increase in
oxidative stress within astrocytes (Table 5). Since GSH synthesis is highly dependent on the
availability of free Cys (the levels of which are extremely low inside and outside cells) [29],
we also measured GGT activity and rates of Cys and cystine uptake. As shown in Table 6B,
advanced ALS progression is associated with an increase in GGT activity, no changes in
the rate of extracellular Cys uptake and a decrease in cystine uptake. Cells do not transport
intact GSH from the extracellular space [30]. GGT is the only enzyme that cleaves the
γ-glutamyl-cysteine peptide bond in GSH [31], thus releasing γ-Glu and cysteinylglycine,
which is further cleaved into Cys and Gly by plasma-membrane-bound dipeptidases [32].
Free γ-glutamyl amino acids Cys and Gly can serve as GSH precursors [33]. Hence, our data
suggest that extracellular GSH is the main source of Cys for astrocytes during advanced
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ALS progression. To further test this postulate, we investigated the effect on astrocyte GSH
levels of specific inhibitors of GGT activity (acivicin) [34], Cys uptake by the ASC transport
system for neutral amino acids [(1)-amino(1-(3,5-dichlorophenyl)-3,5-dimethyl-1H-pyrazol-
4-yl)acetic acid, ACPP] [35] or cystine uptake by the Xc- cystine/glutamate antiporter
(sulfasalazine, SSZ) [36]. These are the main carriers of Cys and cystine in mammalian cells
(see Obrador [37]). As shown in Table 7, GSH depletion in astrocytes is more profound in
the presence of specific inhibitors of GGT or ASC-mediated Cys transport.
Table 5. GSH/GSSG levels and GCL activity in astrocytes isolated from wild-type and ALS mice. Data
are mean values ± SD for n = 9. * p < 0.01 comparing values obtained in ALS models versus the wild-
type controls. + p < 0.01 comparing advanced state of progression versus onset of symptomatology.
WT SOD1G93A FUS-R521C
Onset Adv. Onset Adv.
GSH (nmol/106 cells) 23.1 ± 3.1 24.5 ± 2.7 12.9 ± 1.8 *,+ 22.3 ± 2.5 13.7 ± 2.9 *,+
GSSG (nmol/106 cells) 0.7 ± 0.2 0.8 ± 0.2 1.9 ± 0.4 *,+ 0.7 ± 0.3 1.6 ± 0.5 *,+
GCL (mU/106 cells) 68 ± 17 75 ± 14 123 ± 25 *,+ 65 ± 12 117 ± 31 *,+
Table 6. Supply of amino-acid precursors for GSH synthesis, GGT activity and cyst(e)ine uptake in
astrocytes isolated from wild-type and ALS mice at an advanced state of progression. (A) Amino-acid
levels in circulating blood. (B) GGT activity and rates of Cys and cystine uptake. To measure Cys
and cystine uptake, astrocytes were incubated in the presence of 0.2 µCi/mL of [35S]Cys and 10 uM
Cys or 0.5 µCi/mL of [35S]cystine and 100 uM cystine (labeled amino acids were obtained from
PerkinElmer, Waltham, MA, USA). Maximum rates of Cys and cystine uptake were reached at approx.
2 and 20 min of incubation, respectively. Data are mean values ± SD for n = 7. * p < 0.01 comparing
values obtained in ALS models versus wild-type controls.
A Amine Acid Concentration (µM) in Whole Blood
WT SOD1G93A FUS-R521C
Gln 510 ± 63 493 ± 29 455 ± 55
Glu 123 ± 36 136 ± 21 115 ± 29
Gly 306 ± 77 277 ± 45 285 ± 53
Ser 151 ± 27 140 ± 31 130 ± 20
Meth 55 ± 12 50 ± 10 46 ± 9
Cyst(e)ine 18 ± 3 14 ± 2 15 ± 3
B GGT Activity and Cyst(e)ine Uptake
WT SOD1G93A FUS-R521C
GGT
(mU/106 cells) 15.3 ± 2.4 25.7 ± 3.9 * 23.2 ± 4.0 *
Cys uptake
(nmol/mg prot·min) 2.1 ± 0.5 2.0 ± 0.3 2.2 ± 0.3
Cystine uptake
(nmol/mg prot·min) 24.5 ± 3.5 10.6 ± 1.7 * 11.7 ± 2.2 *
3.5. In Astrocytes, Advanced ALS Progression Is Associated with an Increase in GSH Efflux and
ROS Generation
As described in Table 5, at an advanced state of progression, GSH levels in astrocytes
decrease in the two models of ALS studied, whereas GSSG levels increase, facts suggesting
an increase in oxidative stress. We further studied the underlying mechanisms, and as
shown in Table 8, ROS generation increases in astrocytes isolated from ALS mice at an
advanced state of progression compared to astrocytes from WT controls. The increase
in ROS generation is associated with an increase in O2 consumption, which may reflect
the high metabolic activity associated to the reactive astrocyte phenotype linked to the
progression of the disease. However, in the group of enzymes studied, only SOD1 activity
was found to be significantly higher in the astrocytes of the ALS mice compared to WT
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controls (Table 8, Figure 4). GSH efflux was also found to increase in both models, as
compared to WT controls (Table 8). This increase in GSH efflux may also be facilitated by
IL6 in astrocytes (as in hepatocytes), given that we observed that anti-IL6R mAbs prevents
GSH depletion in perifused astrocytes (results not shown). This all indicates that the
increase in ROS generation is not counteracted within the astrocytes. It is obvious that
an increase in ROS generation by reactive astrocytes may cause damage to neighboring
MNs. In a previous report, we observed that cytosolic GSH levels in MNs isolated from
SOD1G93A mice do not change as the disease progresses [6], which means that an increase
in GSH efflux from astrocytes does not necessarily imply an increase in MNs.
Table 7. Effect of inhibition of GGT activity or Cys/cystine uptake on GSH levels in astrocytes. As-
trocytes isolated from wild-type and ALS mice at an advanced state of progression were incubated in
the absence or presence of acivicin (0.05 mM), ACPP [(1)-amino(1-(3,5-dichlorophenyl)-3,5-dimethyl-
1H-pyrazol-4-yl)acetic acid, 0.1 mM] or SSZ (sulfasalazine, 0.2 mM) during a 24 h-time period before
measuring GSH levels. The culture medium contained extracellular GSH and cyst(e)ine at a concen-
tration of 10 a 1 mM, respectively. Data are mean values± SD for n = 5–6. * p < 0.01 comparing values




Control 22.7 ± 3.4 13.2 ± 2.0 * 14.1 ± 2.4 *
Acivicin 7.5 ± 1.7 + 3.1 ± 1.1 *,+ 3.0 ± 0.7 *,+
ACPP 8.0 ± 1.9 + 3.5 ± 1.2 *,+ 3.1 ± 0.9 *,+
SSZ 16.6 ± 2.3 + 10.2 ± 1.8 * 11.3 ± 1.5 *
Table 8. ROS generation and GSH efflux in astrocytes isolated from wild-type and ALS mice. All
parameters (see Methods) were determined in astrocytes isolated from wild-type or ALS mice at an
advanced state of progression. Data are mean values ± SD for n = 9. * p < 0.01 comparing values
obtained in ALS models versus wild-type controls.
WT SOD1G93A FUS-R521C
ROS
H2O2 (nmol/106 cells·min) 0.69 ± 0.08 1.38 ± 0.29 * 1.16 ± 0.24 *
O2•− (nmol/106 cells·min) 0.30 ± 0.05 0.77 ± 0.12 * 0.63 ± 0.17 *
ROS and GSH metabolism
SOD1 (U/106 cells) 0.81 ± 0.14 1.62 ± 0.15 * 1.74 ± 0.28 *
SOD2 (U/106 cells) 0.23 ± 0.05 0.31 ± 0.07 0.29 ± 0.05
CAT (mU/106 cells) 1.50 ± 0.24 1.85 ± 0.36 2.14 ± 0.51
GPX (mU/106 cells) 3.06 ± 0.84 4.25 ± 0.96 5.06 ± 0.71 *
GSR (mU/106 cells) 5.22 ± 0.53 7.70 ± 1.25 * 7.20 ± 1.46
GSH efflux (nmol/106 cells·h) 5.3 ± 0.8 9.4 ± 1.3 * 10.2 ± 1.5 *
O2 consumption (pmol/106
cells·min) 483 ± 63 725 ± 84 * 667 ± 75 *
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4. Discussion 
ALS progression is associated with severe diffuse astrogliosis, which can be a conse-
quence of neurotoxic insults, diffuse trauma, diffuse ischemia, or different types of infec-
tion [38]. Reactive astrocytes show changes in gene expression, with pronounced upregu-
lation of glial fibrillary acidic protein, hypertrophy and dispersed proliferation and can 
cause inhibition of axonal regeneration [39] and favor the arrival of inflammatory cells 
[40]. Therefore, mechanisms that can trigger chronic neurodegeneration. Indeed, reactive 
astrocytes surround degenerating MNs in ALS patients and ALS rodent models [41]. Nev-
ertheless, the mechanisms underlying the potential damaging role of astrocytes still are a 
question of debate. 
IL6 is upregulated in the CNS of patients affected by neuroinflammation of different 
etiologies [8], as well as in murine models of brain injury [42]. Its pro-inflammatory trans-
signaling pathway, shown to mediate neurodegeneration in mice, depends on a soluble 
form of IL-6R capable of binding IL-6 and stimulating a response on distal cells that ex-
press β-receptor glycoprotein 130 [43]. IL6 knockout mice show a lower inflammatory re-
sponse and neuroglial activation [44,45], increased oxidative stress [46], decreased lym-
phocyte recruitment [47] and a low rate of recovery and healing [48], all suggesting that 
IL6 may be a double-edged sword, particularly in chronic pathological processes, as is the 
case with ALS. As previously suggested concerning murine models of metastatic mela-
noma [14], we found that IL6 also promotes the release of GSH from the liver in the two 
ALS models assayed (Table 3). GSH synthesis and efflux are significantly increased, as 
compared to WT controls, in the hepatocytes of ALS mice at an advanced state of disease 
progression (Tables 1 and 3). The consequent increase in blood GSH facilitates an interor-
gan/cellular flow that can be potentially used by astrocytes and transferred to MNs. Over-
all, this mechanism represents a protective effect for MNs, promoted by the increased lev-
els of IL6 in blood and CSF (Figure 2). 
Binding of IL6 to its receptor initiates a signal-transduction cascade through different 

























































Figure 4. Expression and levels of GSH- and oxidative-stress-related enzymes in wild-type and ALS mice. (A) Data,
expressed as fold change (quantitative RT-PCR; see Methods for calculations), show mean values ± SD for five different
mice. (B) Western blots were performed in cell samples obtained from astrocytes isolate from wild-type mice and
ALS mice at an advanced state of progression, thus facilitating corr lations with the enzyme act vities displayed in
Tables 5, 6B and 8. (C) Densitometric analysis of the Western blots represents the mean alues ± SD for five different mice
per molecule. * p < 0.05, ** p < 0.01 comparing ALS mice versus wild-type controls.
4. iscussion
ALS ro ressi is ss ci te it se ere diffuse astrogliosis, which can be a con-
sequence of neurotoxic insults, diffuse trauma, diffuse ischemia, or different types of
infection [38]. Reactive astrocytes show changes in gene expression, with pronounced
upregulation of glial fibrillary acidic protein, hypertrophy and dispersed proliferation
and can cause inhibition of axonal regeneration [39] and favor the arrival of inflammatory
cells [40]. Therefore, mechanisms that can trigger chronic neurodegeneration. Indeed, reac-
tive astrocytes surround degenerating MNs in ALS patients and ALS rodent models [41].
Nevertheless, the mechanisms underlying the potential damaging role of astrocytes still
are a question of debate.
IL6 is upregulated in the CNS of patients affected by neuroinflammation of different
etiologies [8], as well as in murine models of brain injury [42]. Its pro-inflammatory trans-
signaling pathway, shown to mediate neurodegeneration in mice, depends on a soluble
form of IL-6R capable of binding IL-6 and stimulating a response on distal cells that express
β-receptor glycoprotein 130 [43]. IL6 knockout mice show a lower inflammatory response
and neuroglial activation [44,45], increased oxidative stress [46], decreased lymphocyte
recruitment [47] and a low rate of recovery and healing [48], all suggesting that IL6 may be
a double-edged sword, particularly in chronic pathological processes, as is the case with
ALS. As previously suggested concerning murine models of metastatic melanoma [14],
we found that IL6 also promotes the release of GSH from the liver in the two ALS models
assayed (Table 3). GSH synthesis and efflux are significantly increased, as compared to
WT controls, in the hepatocytes of ALS mice at an advanced state of disease progression
(Tables 1 and 3). The consequent increase in blood GSH facilitates an interorgan/cellular
flow that can be potentially used by astrocytes and transferred to MNs. Overall, this
mechanism represents a protective effect for MNs, promoted by the increased levels of IL6
in blood and CSF (Figure 2).
Binding of IL6 to its receptor initiates a signal-transduction cascade through different
transcription factors, Janus kinases (JAKs) and signal transducers, as well as activators of
transcription (STATs) [49]. Whether treatment with anti-IL6 or anti-IL6R alter the expression
of the mutant SOD1 and/or the mutant FUS is unknown and should be investigated. What
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is remarkable is the fact that despite the different phenotypes of the two ALS models, the
effect of anti-IL6 treatment on GSH levels is quite similar (Table 3).
It has been demonstrated that astrocytes provide Cys to neurons by releasing GSH [13]
via the multi-drug-resistant protein 1 [50]. Astrocytes can degrade extracellular GSH via
GGT and release Cys-Gly, which is broken down by the action of a plasma-membrane-
bound dipeptidase [37]. Then, free Cys, which is rate-limiting for GSH synthesis, can be
taken up through the ASC system [37] (Table 7). The blood supply of all other amino-acid
precursors for GSH synthesis is not limited in ALS mice (Table 6A). Importantly, although
the rate of cystine uptake by astrocytes decreases as the disease progresses, the rate of
Cys uptake is not affected (Table 6B). The effect of the inhibitors (Table 7) seems to be
relative to the initial control GSH levels in each case. What is important is the fact that
inhibition of GGT activity or Cys uptake causes a higher GSH depletion than inhibition of
cystine uptake. Cys levels are extremely low (outside and inside cells), and consequently,
Cys uptake is highly dependent on the generation of Cys from extracellular GSH (via
the reaction catalyzed by GGT). GGT activity in astrocytes was found to increase, as
compared to WT controls, in ALS mice (Table 6B). However, GGT activity in MNs isolated
from SOD1G93A mice at an advanced state of progression is lower than its equivalent in
astrocytes [6]. Since astrocytes outnumber neurons by over fivefold [51], it is obvious that
astrocytes have the highest capacity to metabolize extracellular GSH. Taken together, these
experimental facts indicate that GSH synthesis in MNs is highly dependent on GSH supply
from astrocytes, which, in turn, depends on the interorgan flow from the liver controlled
by IL6.
As shown in Table 8, in both ALS models, generation of ROS by astrocytes increases
at an advanced state of disease progression. Previously, we found that GSH levels in MNs
isolated from SOD1G93A mice at an advanced state of progression are slightly higher than
the levels measured in MNs from WT control mice [6]. However, GSSG levels (which
indirectly reflect a higher exposure to ROS) increase by approx. 100% [6]. An increase
in O2 consumption and GSH efflux (Table 8), as well as the consequent decrease in GSH
levels (Table 5), may explain the increase in ROS generation by astrocytes. ROS could
be a direct cause of oxidative damage in neighboring MNs. The fact that SOD1 and
SOD2, two key antioxidant enzyme activities, decrease in MNs of SOD1G93A mice as the
disease progresses [6] sets up a cumulative-damage scenario. As shown in Table 5, GSH
levels decrease in astrocytes isolated from ALS mice at an advanced state of progression,
compared to onset or WT. However, GCL activity increases (Table 5), and Cys uptake
remains unchanged (Table 6B). Nevertheless, the increases in GSSG (Table 5) and ROS
generation (both indicating more oxidative stress), as well as the increase in GSH efflux
(Table 8), explain why GSH decreases. An increase in ROS exposure and a decrease in its
antioxidant-defense capacity may be key factors in the death of MNs.
5. Conclusions
An increase in circulating levels of IL6 (released by glial and inflammatory cells)
promotes the release of GSH from the liver (a physiological reservoir of this tripeptide).
The increased availability of extracellular GSH facilitates its transfer, via astrocytes, to MNs
and favor its antioxidant defense. However, in advanced stages of the disease, this process
is associated with an increase in ROS generation by astrocytes. Oxidative stress can cause
cumulative damage to MNs, as well as their death. From the results described herein, it
seems obvious that maintaining GSH levels in astrocytes, and consequently in MNs, can
help to slow down the progression of the disease. Since the availability of Cys is a limiting
factor for the synthesis of GSH, a direct donor of Cys, e.g., N-acetylcysteine, which easily
crosses the plasma membrane, could be a direct drug solution. Nevertheless, maintenance
of GSH homeostasis in ALS is only part of the potential benefits of combined strategies
targeting different pathways/molecules at the same time [52].
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